{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with event to calculate upper limit","groupId":"OG000","lowerLimit":"6.8","upperLimit":"NA","value":"30.2"},{"groupId":"OG001","lowerLimit":"22.4","upperLimit":"52.5","value":"35.3"},{"comment":"Insufficient number of participants with event to calculate upper limit and median","groupId":"OG002","lowerLimit":"26.3","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"description":"DoR is defined as thr time from the initial documented response (partial response or better) to the first confirmed progressive disease or until death from any cause. Participants without documented progression will be censored at the time of their last response assessment.\n\nCR=Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow VGPR=Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \\< 100 mg per 24 hours PR=≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \\< 200 mg per 24 hours. Based on Kaplan-Meier Estimates","dispersionType":"95% Confidence Interval","groups":[{"description":"(Pomalidomide + low dose Dexamethasone) in participants with 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old).","id":"OG000","title":"Cohort A"},{"description":"(Pomalidomide + Daratumumab + low dose Dexamethasone) in participants with 1 or 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old). DARA was administered intravenously (IV) at a starting dose of 16 mg/kg.","id":"OG001","title":"Cohort B"},{"description":"(Pomalidomide + Daratumumab + low dose Dexamethasone) in Japanese participants with 1 or 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old). DARA was administered intravenously (IV) at a starting dose of 16 mg/kg.","id":"OG002","title":"Cohort C"}],"paramType":"MEDIAN","populationDescription":"All responders (PR, VGPR, CR)","reportingStatus":"POSTED","timeFrame":"From first dose until the first documented disease progression, or death whichever occurs first (Up to 130 months)","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}